Of the different treatments for early prostate cancer, hypofractionated external-beam radiotherapy is one of the most interesting and studied options.
Methods
The main objective of this phase II clinical study is to evaluate the feasibility, in terms of the incidence of acute side effects, of a new ultra-hypofractionated scheme for low- or intermediate-risk prostate cancer patients treated with the latest imaging and radiotherapy technology, allowing dose escalation to the dominant intraprostatic lesion identified by multiparametric magnetic resonance imaging. Secondary endpoints of the study are the evaluation of the long-term tolerability of the treatment in terms of late side effects, quality of life, and efficacy (oncological outcome).
Results
The study is ongoing, and we expect to complete recruitment by the end of 2016.
Conclusions
Like in previous studies, we expect ultra-hypofractionated radiation treatment for prostate cancer to be well tolerated and effective.
Jereczek-FossaBAOrecchiaREvidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer. Radiother Oncol2007;84 (2)197–215
2.
Prostate cancer. In: National Comprehensive Cancer Network clinical practice guidelines in oncology, version 2.2016. Jenkintown, PA:National Comprehensive Cancer Network 2011. Available from http://www.nccn.org/professionals/physician_gls/default.asp.
3.
VianiGAStefanoEJAfonsoSLHigher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys2009;74 (5)1405–1418
4.
TurkbeyBPintoPAChoykePLImaging techniques for prostate cancer: implications for focal therapy. Nat Rev Urol2009;6 (4)191–203
5.
LangenKMJonesDTOrgan motion and its management. Int J Radiat Oncol Biol Phys2001;50 (1)265–278
6.
PesceGAClivioACozziLEarly clinical experience of radiotherapy of prostate cancer with volumetric modulated arc therapy. Radiat Oncol2010;5 (1)54
7.
KaminoYTakayamaKKokuboMDevelopment of a four-dimensional image-guided radiotherapy system with a gimbaled X-ray head. Int J Radiat Oncol Biol Phys2006;66 (1)271–278
8.
CoenJJZietmanALProton radiation for localized prostate cancer. Nat Rev Urol2009;6 (6)324–330
9.
BrennerDJHallEJFractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys1999;43 (5)1095–1101
10.
MiralbellRRobertsSAZubizarretaEHendryJHDose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys2012;82 (1)e17–e24
11.
HendersonDRTreeACvan AsNJStereotactic body radiotherapy for prostate cancer. Clin Oncol (R Coll Radiol)2015;27 (5)270–279
12.
ArcangeliGFowlerJGomelliniSAcute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys2011;79 (4)1013–1021
13.
PawlickiTCotrutzCKingCProstate cancer therapy with stereotactic body radiation therapy. Front Radiat Ther Oncol2007;40395–406
14.
VavassoriAJereczek-FossaBABeltramoGImage-guided robotic radiosurgery as salvage therapy for locally recurrent prostate cancer after external beam irradiation: retrospective feasibility study on six cases. Tumori2010;96 (1)71–75
15.
VergisRCorbishleyCMNormanARIntrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol2008;9 (4)342–351
16.
HousriNNingHOndosJParameters favorable to intraprostatic radiation dose escalation in men with localized prostate cancer. Int J Radiat Oncol Biol Phys2011;80 (2)614–620
17.
BaumanGHaiderMVan der HeideUAMénardCBoosting imaging defined dominant prostatic tumors: a systematic review. Radiother Oncol2013;107 (3)274–281
18.
ArcangeliSScorsettiMAlongiFWill SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review. Crit Rev Oncol Hematol2012;84 (1)101–108
19.
CiardoDBazaniAPansiniFPO-0995: Evaluation of VMAT-RapidArc, IMRT-VERO and proton-RT for a hypofractionated scheme of prostate cancer treatment. Radiother Oncol2015;115Suppl 1S533–S534
20.
CoxJDStetzJPajakTFToxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys1995;31 (5)1341–1346
21.
US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. National Institutes of Health, National Cancer Institute 2009, 4.03.
22.
ChenLNSuySUhmSStereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol2013;8 (1)58
23.
AlsadiusDHedelinMLundstedtDPetterssonNWilderängUSteineckGMean absorbed dose to the anal-sphincter region and fecal leakage among irradiated prostate cancer survivors. Int J Radiat Oncol Biol Phys2012;84 (2)e181–e185
24.
KavanaghBDPanCCDawsonLARadiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys2010;763 SupplS101–S107
25.
CarozziFTamburrinoLBisanziSAre biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?J Cancer Res Clin Oncol2016;142 (1)201–212
26.
KachrooNGnanapragasamVJThe role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review. J Cancer Res Clin Oncol2013;139 (1)1–24
27.
Romero OteroJGarcia GomezBCampos JuanateyFTouijerKAProstate cancer biomarkers: an update. Urol Oncol2014;32 (3)252–260
28.
SimonROptimal two-stage designs for phase II clinical trials. Control Clin Trials1989Mar10 (1)1–10
